Yinlitinib

To evaluate the safety and tolerability of single and continuous administration of inlitinib maleate in patients with advanced solid tumors, determine the maximum tolerated dose and dose-limiting toxicity; recommend the dosage and dosing regimen for subsequent clinical trials. To characterize the pharmacokinetic properties and pharmacokinetic parameters of tumor patients after oral administration; to evaluate the anti-tumor activity. To evaluate the overexpression, gene amplification, mutation of tumor tissue biomarkers, and the correlation of related genes or proteins in the blood with the clinical efficacy of DNT04110.